Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
about
Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancerCyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugsPI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer CellsEGFR-mutated lung cancer: a paradigm of molecular oncology.Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study.Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyPhase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursCellular Recognition and Repair of Monofunctional-Intercalative Platinum--DNA AdductsRRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQAThe cell's nucleolus: an emerging target for chemotherapeutic intervention.GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluationEpidermal growth factor receptor as a therapeutic target in veterinary oncology.An indolylquinoline derivative promotes apoptosis in human lung cancer cells by impairing mitochondrial functions.Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients.Inhalable microspheres embedding chitosan-coated PLGA nanoparticles for 2-methoxyestradiol.Large-Pore Functionalized Mesoporous Silica Nanoparticles as Drug Delivery Vector for a Highly Cytotoxic Hybrid Platinum-Acridine Anticancer Agent.A triazole-conjugated benzoxazone induces reactive oxygen species and promotes autophagic apoptosis in human lung cancer cells.Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting.
P2860
Q26998615-6E9AC7C2-9144-4199-80DD-2544954EBCB4Q33801128-957A3FA6-156C-44FE-AAF2-33ABEBBFFBD0Q33912340-60480253-6291-4C32-AB95-7B84A3086104Q34406334-6D18B5F4-2404-474C-AD78-F683ABFB536FQ34572581-398B33D9-B370-4BB3-8358-C5899950ACFDQ35510634-4CF6BBE1-2BA2-42B2-A529-A242EBC71D5EQ36071392-2663FA4E-4B6F-40E7-94DC-4C3C048EE1A0Q36387910-0DF336BC-C4FD-4B40-843D-3F80A89DA7BAQ36460000-C3B64512-8D36-454D-90E4-E1A2F4B71F88Q36566472-1E2DD670-6D7B-4793-A5F6-CEC32DC6A463Q37061902-82419252-2287-4ED8-B8CE-69C22480D6EBQ37484539-0F46B402-4262-4C5F-B318-59041B97883CQ37591930-55E59E39-48FD-4AD6-8B74-87784A24CBE9Q37875223-9CFE63B6-124B-4DFE-AFF2-AB2A4F276161Q38836961-7E29B12A-A7DA-4C72-BA66-4BCA8EFED86CQ38956330-6FA7F8BD-0199-4850-BB89-1A67246363EEQ39034958-570A5FDB-E7F2-43B1-8CB6-8D5831B71370Q44869674-917FC949-94B5-49A9-A48E-8803E5C96286Q46252289-151F958E-BCB6-4185-9BE5-B0CF8C2D577BQ47627194-0F1F61C1-072E-4330-833A-4971EE5609F6
P2860
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
@en
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
@nl
type
label
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
@en
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
@nl
prefLabel
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
@en
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
@nl
P2860
P356
P1433
P1476
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
@en
P2093
H A Burris
P2860
P2888
P356
10.1038/ONC.2009.196
P407
P478
28 Suppl 1
P577
2009-08-01T00:00:00Z